Download MendeleyAn engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry.
Lin, X., Guo, L., Lin, S., Chen, Z., Yang, F., Yang, J., Wang, L., Wen, A., Duan, Y., Zhang, X., Dai, Y., Yin, K., Yuan, X., Yu, C., He, B., Cao, Y., Dong, H., Li, J., Zhao, Q., Lu, G.(2022) Emerg Microbes Infect 11: 1920-1935
- PubMed: 35757908 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1080/22221751.2022.2095308
- Primary Citation Related Structures:
7Y9N - PubMed Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related sarbecoviruses enter host cells by receptor-recognition and membrane-fusion. An indispensable step in fusion is the formation of 6-helix bundle by viral spike heptad repeats 1 and 2 (HR1 and HR2). Here, we report the construction of 5-helix bundle (5HB) proteins for virus infection inhibition. The optimal construct inhibits SARS-CoV-2 pseudovirus entry with sub-micromolar IC50. Unlike HR2-based peptides that cannot bind spike in the pre-fusion conformation, 5HB features with the capability of binding to pre-fusion spike. Furthermore, 5HB binds viral HR2 at both serological- and endosomal-pH, highlighting its entry-inhibition capacity when SARS-CoV-2 enters via either cell membrane fusion or endosomal route. Finally, we show that 5HB could neutralize S-mediated entry of the predominant SARS-CoV-2 variants and a wide spectrum of sarbecoviruses. These data provide proof-of-concept evidence that 5HB might be developed for the prevention and treatment of SARS-CoV-2 and other emerging sarbecovirus infections.
- West China Hospital Emergency Department (WCHED), State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Organizational Affiliation:
